Publications by authors named "E Olmetto"
Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Curr Oncol
November 2024
Article Synopsis
- A study was conducted to assess current treatment practices for extensive-stage small-cell lung cancer (ES-SCLC) among Italian clinicians, especially regarding the use of radiation therapy.
- The survey involved 225 cancer care professionals, with 90 responding, mainly radiation oncologists with significant experience; the results highlighted a preference for combining chemotherapy with immunotherapy and the common use of prophylactic cranial irradiation (PCI).
- The findings revealed variability in treatment approaches for ES-SCLC, indicating a need for further clinical trials and improved multidisciplinary strategies for managing these patients.
Background: The present study evaluates the utility of NGS analysis of circulating free DNA (cfDNA), which incorporates small amounts of tumor DNA (ctDNA), at diagnosis or at disease progression (PD) in NSCLC patients.
Methods: Comprehensive genomic profiling on cfDNA by NGS were performed in NSCLC patients at diagnosis (if tissue was unavailable/insufficient) or at PD to investigate potential druggable molecular aberrations. Blood samples were collected as routinary diagnostic procedures, DNA was extracted, and the NextSeq 550 Illumina platform was used to run the Roche Avenio ctDNA Expanded Kit for molecular analyses.
Radical cystectomy (RC) is considered the standard treatment for muscle invasive bladder cancer (MIBC). However, RC is often burdened by significant impact on quality of life (QoL); Continence preserving methods (e.g.
View Article and Find Full Text PDFPurpose: Up to 47% of patients with localized prostate cancer (PCa) treated with radiotherapy (EBRT) eventually develop local recurrence. To date, no clear consensus exists on optimal management. A growing body of interest supports the use of stereotaxic re-irradiation (rSBRT), with promising oncological outcomes and low toxicity profile.
View Article and Find Full Text PDFArticle Synopsis
- After the PACIFIC trial, the combination of concurrent chemo-radiotherapy followed by 1 year of durvalumab for unresectable NSCLC (non-small cell lung cancer) has become the standard treatment, particularly for patients with a PD-L1 score of ≥ 1%.
- New challenges have emerged in clinical practice, including how to treat patients with specific genetic mutations, manage disease recurrence after surgery, and address cases where patients progress during or after durvalumab therapy.
- A multidisciplinary approach is crucial for managing stage III NSCLC, emphasizing the need for tumor genotyping and re-biopsy for optimal treatment planning and distinguishing between curable and non-curable recurrences.